Immune-Mediated Inflammatory Diseases Market Size, Share Detailed Report 2026 to 2035

Report Id: 2889 Pages: 165 Last Updated: 10 July 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Immune-Mediated Inflammatory Diseases Market :

Immune-Mediated Inflammatory Diseases Market By Indication-

  • Asthma, Chronic Obstructive Pulmonary Diseases (COPD)
  • Inflammatory Bowel Disease (IBD)
  • Systemic Lupus Erythematosus (SLE)
  • Rheumatoid Arthritis (RA)
  • Psoriasis
  • Others

immune mediated

Immune-Mediated Inflammatory Diseases Market By Treatment Type-

  • Traditional Drugs
  • Biologic Therapies
  • Novel Therapies

Immune-Mediated Inflammatory Diseases Market By Route of Administration-

  • Oral
  • Parenteral
  • Others

Immune-Mediated Inflammatory Diseases Market By End-Users-

  • Hospitals
  • Specialty Clinics
  • Others

Immune-Mediated Inflammatory Diseases Market By Distribution Channel-

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Immune-Mediated Inflammatory Diseases Market By Region-

  • North America-
    • The US
    • Canada
  • Europe-
    • Germany
    • The UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific-
    • China
    • Japan
    • India
    • South Korea
    • South East Asia
    • Rest of Asia Pacific
  • Latin America-
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  •  Middle East & Africa-
    • GCC Countries
    • South Africa
    • Rest of Middle East and Afric

Chapter 1.       Methodology and Scope

1.1.      Research Methodology

1.2.      Research Scope & Assumptions

Chapter 2.       Executive Summary

Chapter 3.       Global Immune-Mediated Inflammatory Diseases Market Snapshot

Chapter 4.       Global Immune-Mediated Inflammatory Diseases Market Variables, Trends & Scope

4.1.      Market Segmentation & Scope

4.2.      Drivers

4.3.      Challenges

4.4.      Trends

4.5.      Investment and Funding Analysis

4.6.      Porter's Five Forces Analysis

4.7.      Incremental Opportunity Analysis (US$ MN), 2024-2031

4.8.      Global Immune-Mediated Inflammatory Diseases Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031

4.9.      Competitive Landscape & Market Share Analysis, By Key Player (2023)

4.10.    Use/impact of AI on Immune-Mediated Inflammatory Diseases Industry Trends

Chapter 5.       Immune-Mediated Inflammatory Diseases Market Segmentation 1: By Indication, Estimates & Trend Analysis

5.1.      Market Share by Indication, 2023 & 2031

5.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following  Indication:

5.2.1.   Asthma, Chronic Obstructive Pulmonary Diseases (COPD)

5.2.2.   Inflammatory Bowel Disease (IBD)

5.2.3.   Systemic Lupus Erythematosus (SLE)

5.2.4.   Rheumatoid Arthritis (RA)

5.2.5.   Psoriasis

5.2.6.   Others

Chapter 6.       Immune-Mediated Inflammatory Diseases Market Segmentation 2: By Treatment Type Area, Estimates & Trend Analysis

6.1.      Market Share by Treatment Type Area, 2023 & 2031

6.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatment Types Area:

6.2.1.   Traditional Drugs

6.2.2.   Biologic Therapies

6.2.3.   Novel Therapies

Chapter 7.       Immune-Mediated Inflammatory Diseases Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis

7.1.      Market Share by Route of Administration, 2023 & 2031

7.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administrations:

7.2.1.   Oral

7.2.2.   Parenteral

7.2.3.   Others

Chapter 8.       Immune-Mediated Inflammatory Diseases Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis

8.1.      Market Share by Distribution Channel, 2023 & 2031

8.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:

8.2.1.   Hospital Pharmacy

8.2.2.   Retail Pharmacy

8.2.3.   Others

Chapter 9.       Immune-Mediated Inflammatory Diseases Market Segmentation 5: By End User, Estimates & Trend Analysis

9.1.      Market Share by End User, 2023 & 2031

9.2.      Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:

9.2.1.   Hospitals

9.2.2.   Specialty Clinics

9.2.3.   Others

Chapter 10.     Immune-Mediated Inflammatory Diseases Market Segmentation 6: Regional Estimates & Trend Analysis

10.1.    Global Immune-Mediated Inflammatory Diseases Market, Regional Snapshot 2023 & 2031

10.2.    North America

10.2.1. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.2.1.1.          US

10.2.1.2.          Canada

10.2.2. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031

10.2.3. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031

10.2.4. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

10.2.5. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

10.2.6. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031

10.3.    Europe

10.3.1. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.3.1.1.          Germany

10.3.1.2.          U.K.

10.3.1.3.          France

10.3.1.4.          Italy

10.3.1.5.          Spain

10.3.1.6.          Rest of Europe

10.3.2. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031

10.3.3. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031

10.3.4. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

10.3.5. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

10.3.6. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031

10.4.    Asia Pacific

10.4.1. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.4.1.1.          India

10.4.1.2.          China

10.4.1.3.          Japan

10.4.1.4.          Australia

10.4.1.5.          South Korea

10.4.1.6.          Hong Kong

10.4.1.7.          Southeast Asia

10.4.1.8.          Rest of Asia Pacific

10.4.2. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024- 2031

10.4.3. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031

10.4.4. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031

10.4.5. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

10.4.6. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By End User, 2024-2031

10.5.    Latin America

10.5.1. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.5.1.1.          Brazil

10.5.1.2.          Mexico

10.5.1.3.          Rest of Latin America

10.5.2. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031

10.5.3. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031

10.5.4. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

10.5.5. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

10.5.6. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031

10.6.    Middle East & Africa

10.6.1. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

10.6.1.1.          GCC Countries

10.6.1.2.          Israel

10.6.1.3.          South Africa

10.6.1.4.          Rest of Middle East and Africa

10.6.2. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031

10.6.3. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031

10.6.4. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031

10.6.5. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031

10.6.6. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031

Chapter 11.     Competitive Landscape

11.1.    Major Mergers and Acquisitions/Strategic Alliances

11.2.    Company Profiles

 

11.2.1. Pfizer Inc

11.2.1.1.          Business Overview

11.2.1.2.          Key Product/Service Offerings

11.2.1.3.          Financial Performance

11.2.1.4.          Geographical Presence

11.2.1.5.          Recent Developments with Business Strategy

11.2.2. Abbvie Inc.

11.2.3. Novartis AG

11.2.4. Amgen Inc.

11.2.5. Boehringer Ingelheim International GmbH.

11.2.6. Merck & Co Inc.

11.2.7. Sun Pharmaceutical Industries Ltd.

11.2.8. Teva Pharmaceuticals Industries Ltd.

11.2.9. AstraZeneca

11.2.10.           Ampio Pharmaceuticals Inc.

11.2.11.           Lilly

11.2.12.           Zydus Group

11.2.13.           Akorn, Incorporated

11.2.14.           Daiichi Sankyo Company, Limited

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4851
Security Code field cannot be blank!

Frequently Asked Questions

The Immune-Mediated Inflammatory Diseases Market Size is estimated to grow at a 7.10% CAGR during the forecast period for 2024-2031.

Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Merck & Co Inc. (U.S.), Zydus Group (India

Indication, Treatment Type, Indication, Route Of Administration, End-User, And Distribution Channel are the key segments of the Immune-Mediated Inflam

North American market is leading the Immune-Mediated Inflammatory Diseases Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying